MA38175B1 - Lactames fusionnés à un aryle et hétéroaryle - Google Patents
Lactames fusionnés à un aryle et hétéroaryleInfo
- Publication number
- MA38175B1 MA38175B1 MA38175A MA38175A MA38175B1 MA 38175 B1 MA38175 B1 MA 38175B1 MA 38175 A MA38175 A MA 38175A MA 38175 A MA38175 A MA 38175A MA 38175 B1 MA38175 B1 MA 38175B1
- Authority
- MA
- Morocco
- Prior art keywords
- heteroaryl
- aryl
- compounds
- salts
- lactams
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Cette invention concerne des composés de formule générale (i), des sels pharmaceutiquement acceptables de ceux-ci, des compositions pharmaceutiques contenant lesdits composés et sels, et des méthodes d'utilisation desdits composés, sels et compositions pour traiter une croissance cellulaire anormale, y compris le cancer. Dans la formule générale (i), r
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261740596P | 2012-12-21 | 2012-12-21 | |
PCT/IB2013/060682 WO2014097041A1 (fr) | 2012-12-21 | 2013-12-05 | Lactames fusionnés à un aryle et hétéroaryle |
Publications (2)
Publication Number | Publication Date |
---|---|
MA38175A1 MA38175A1 (fr) | 2018-08-31 |
MA38175B1 true MA38175B1 (fr) | 2018-11-30 |
Family
ID=49917684
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA38175A MA38175B1 (fr) | 2012-12-21 | 2013-12-05 | Lactames fusionnés à un aryle et hétéroaryle |
Country Status (47)
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2780013A4 (fr) | 2011-11-18 | 2015-07-01 | Constellation Pharmaceuticals Inc | Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées |
WO2013120104A2 (fr) | 2012-02-10 | 2013-08-15 | Constellation Pharmaceuticals | Modulateurs d'enzymes de modification par méthylation, leurs compositions et utilisations |
AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
UA111305C2 (uk) * | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
CN110684067A (zh) | 2012-12-21 | 2020-01-14 | 艾丽奥斯生物制药有限公司 | 取代的核苷和核苷酸 |
EP2970305B1 (fr) | 2013-03-15 | 2017-02-22 | Constellation Pharmaceuticals, Inc. | Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées |
WO2015023915A1 (fr) | 2013-08-15 | 2015-02-19 | Constellation Pharmaceuticals, Inc. | Dérivés d'indole utilisés en tant que modulateurs d'enzymes de modification du méthyle, compositions et utilisations associées |
ES2721031T3 (es) * | 2014-06-17 | 2019-07-26 | Pfizer | Compuestos de dihidroisoquinolinona sustituidos |
WO2015193768A1 (fr) * | 2014-06-17 | 2015-12-23 | Pfizer Inc. | Lactames à fusion aryle à utiliser en tant que modulateurs ezh2 |
CN107148419A (zh) * | 2014-10-28 | 2017-09-08 | 葛兰素史密斯克莱知识产权(第2 号)有限公司 | Zeste增强子同源物2抑制剂 |
TW201636344A (zh) | 2014-12-05 | 2016-10-16 | 美國禮來大藥廠 | Ezh2抑制劑 |
EP3236962A2 (fr) | 2014-12-23 | 2017-11-01 | University of Copenhagen | Traitement du cancer par inhibition de l'activité de l'ezh2 |
WO2016156085A1 (fr) * | 2015-03-27 | 2016-10-06 | Syngenta Participations Ag | Dérivés hétérobicycliques microbiocides |
UY36758A (es) * | 2015-06-30 | 2016-12-30 | Glaxosmithkline Ip No 2 Ltd | Inhibidores del potenciador del homólogo zeste 2 |
TW201718598A (zh) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ezh2抑制劑 |
US10577350B2 (en) | 2015-08-28 | 2020-03-03 | Constellation Pharmaceuticals, Inc. | Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide |
RS59763B1 (sr) | 2015-11-19 | 2020-02-28 | Jiangsu hengrui medicine co ltd | Derivati benzofurana, postupci njihove pripreme i njihova upotreba u medicini |
CR20180521A (es) * | 2016-05-05 | 2019-01-15 | Glaxosmithkline Ip No 2 Ltd | Inhibidores del potenciador del homólogo zeste 2 |
EP3529242A1 (fr) | 2016-10-19 | 2019-08-28 | Constellation Pharmaceuticals, Inc. | Synthèse d'inhibiteurs d'ezh2 |
CN108699002B (zh) * | 2016-11-11 | 2021-11-09 | 上海海雁医药科技有限公司 | 1,5,7-三取代的异喹啉衍生物、其制法与医药上的用途 |
US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
WO2018210302A1 (fr) | 2017-05-18 | 2018-11-22 | 江苏恒瑞医药股份有限公司 | Formes cristallines du chlore libre dérivé du benzofurane et son procédé de préparation |
JP7125952B2 (ja) | 2017-05-18 | 2022-08-25 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 腫瘍を治療するための薬剤の製造におけるbtk阻害剤との組み合わせでのezh2阻害剤の使用 |
CN106977483A (zh) * | 2017-06-02 | 2017-07-25 | 遵义医学院 | 一种二氟烷基取代的黄酮醇、异黄酮醇和香豆素类化合物的合成方法 |
WO2019097369A1 (fr) | 2017-11-14 | 2019-05-23 | Pfizer Inc. | Polythérapies faisant appel à un inhibiteur de ezh2 |
MX2020007974A (es) | 2018-01-31 | 2020-09-07 | Mirati Therapeutics Inc | Inhibidores de complejo represivo polycomb 2 (prc2). |
EP4155293A1 (fr) * | 2018-06-07 | 2023-03-29 | The Regents of The University of Michigan | Inhibiteurs de prc1 et méthodes de traitement comprenant ces derniers |
JP2021531340A (ja) | 2018-07-09 | 2021-11-18 | フォンダシヨン、アジール、デ、アブグルスFondation Asile Des Aveugles | 眼障害を治療するためのprc2サブユニットの阻害 |
US11999716B2 (en) * | 2018-10-24 | 2024-06-04 | Vanderbilt University | WDR5 inhibitors and modulators |
CN111320582A (zh) * | 2018-12-17 | 2020-06-23 | 江苏恩华药业股份有限公司 | 一种类酰胺类衍生物及其中间体的制备方法 |
KR102689665B1 (ko) * | 2019-02-19 | 2024-07-31 | 한미약품 주식회사 | 신규한 헤테로트리시클릭 유도체 화합물 및 이의 용도 |
KR102386403B1 (ko) * | 2020-08-13 | 2022-04-15 | 한미약품 주식회사 | 신규한 디옥솔로이소퀴놀린온 유도체 화합물 및 이의 용도 |
EP4196483A1 (fr) | 2020-08-13 | 2023-06-21 | Hanmi Pharmaceutical Co., Ltd. | Nouveaux dérivés de dioxoloisoquinolinone et leur utilisation |
WO2022179584A1 (fr) * | 2021-02-26 | 2022-09-01 | 南京药石科技股份有限公司 | Nouvel inhibiteur d'ezh2 et son utilisation |
WO2024126650A1 (fr) | 2022-12-15 | 2024-06-20 | Syngenta Crop Protection Ag | Nouveaux composés bicycliques-carboxamide utiles en tant que pesticides |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3846412A (en) | 1971-03-18 | 1974-11-05 | Lepetit Spa | Dihydro-2-amino-isoquinolines and their derivatives |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
WO2000035298A1 (fr) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing-gum contenant des agents medicamenteux actifs |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
FR2889526B1 (fr) | 2005-08-04 | 2012-02-17 | Aventis Pharma Sa | 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
CA2619462A1 (fr) | 2005-08-16 | 2007-02-22 | Amgen, Inc. | Inhibiteurs de phosphodiesterase 10 |
US20100113415A1 (en) | 2008-05-29 | 2010-05-06 | Rajapakse Hemaka A | Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer |
WO2011103016A2 (fr) | 2010-02-19 | 2011-08-25 | The Regents Of The University Of Michigan | Compositions et méthodes d'inhibition d'ezh2 |
EP2566328B1 (fr) | 2010-05-07 | 2015-03-04 | GlaxoSmithKline LLC | Indazoles |
WO2012005805A1 (fr) | 2010-05-07 | 2012-01-12 | Glaxosmithkline Llc | Aza-indazoles |
PT2566327T (pt) | 2010-05-07 | 2017-05-26 | Glaxosmithkline Llc | Indoles |
EP2614369B1 (fr) | 2010-09-10 | 2016-02-03 | Epizyme, Inc. | Procédé de détermination de l'utilité d'inhibiteurs de l'ezh2 humaine |
US8946260B2 (en) | 2010-09-16 | 2015-02-03 | Novartis Ag | 17α-hydroxylase/C17,20-lyase inhibitors |
US20130310379A1 (en) | 2010-11-19 | 2013-11-21 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
EP2681216B1 (fr) * | 2011-02-28 | 2017-09-27 | Epizyme, Inc. | Composés hétéroaryles bicycliques substitués condensés en 6,5 |
JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
TW201733984A (zh) * | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
WO2013049770A2 (fr) | 2011-09-30 | 2013-04-04 | Glaxosmithkline Llc | Méthodes de traitement du cancer |
US9562041B2 (en) | 2012-05-16 | 2017-02-07 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
WO2014049488A1 (fr) | 2012-09-28 | 2014-04-03 | Pfizer Inc. | Composés de benzamide et hétérobenzamide |
LT3067358T (lt) | 2012-12-21 | 2019-11-25 | Gilead Sciences Inc | Policikliniai karbamoilpiridono junginiai ir jų farmacinis panaudojimas |
UA116553C2 (uk) | 2012-12-21 | 2018-04-10 | Санофі | Пептидна сполука - агоніст рецептора glp-1 i glp |
ME03000B (fr) | 2012-12-21 | 2018-10-20 | Plexxikon Inc | Composés et procédés pour la modulation de kinase, et indications associées |
NZ708175A (en) | 2012-12-21 | 2020-06-26 | Hoffmann La Roche | Peptides as oxytocin agonists |
FR3000059A1 (fr) | 2012-12-21 | 2014-06-27 | Saint Gobain Placo | Composition pour plaques de platre et produits obtenus |
UA111305C2 (uk) | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
US9233974B2 (en) | 2012-12-21 | 2016-01-12 | Gilead Sciences, Inc. | Antiviral compounds |
KR102024417B1 (ko) | 2012-12-21 | 2019-11-07 | 에피자임, 인코포레이티드 | 테트라하이드로- 및 디하이드로-이소퀴놀린 prmt5 억제제 및 이의 용도 |
CN110684067A (zh) | 2012-12-21 | 2020-01-14 | 艾丽奥斯生物制药有限公司 | 取代的核苷和核苷酸 |
FR3000065A1 (fr) | 2012-12-21 | 2014-06-27 | Univ Lille Ii Droit & Sante | Composes bicycliques ayant une activite potentialisatrice de l'activite d'un antibiotique actif contre les mycobacteries-composition et produit pharmaceutiques comprenant de tels composes |
ES2721031T3 (es) | 2014-06-17 | 2019-07-26 | Pfizer | Compuestos de dihidroisoquinolinona sustituidos |
-
2013
- 2013-05-12 UA UAA201505087A patent/UA111305C2/uk unknown
- 2013-12-05 EA EA201590879A patent/EA028317B1/ru unknown
- 2013-12-05 ES ES17206218T patent/ES2808987T3/es active Active
- 2013-12-05 RS RS20200917A patent/RS60582B9/sr unknown
- 2013-12-05 ME MEP-2020-147A patent/ME03793B/fr unknown
- 2013-12-05 PL PL13817739T patent/PL2935238T3/pl unknown
- 2013-12-05 EP EP13817739.9A patent/EP2935238B1/fr active Active
- 2013-12-05 EP EP17206218.4A patent/EP3339303B9/fr active Active
- 2013-12-05 PE PE2015001044A patent/PE20151090A1/es active IP Right Grant
- 2013-12-05 LT LTEP17206218.4T patent/LT3339303T/lt unknown
- 2013-12-05 MY MYPI2015701733A patent/MY176307A/en unknown
- 2013-12-05 MD MDA20150052A patent/MD4664C9/ro not_active IP Right Cessation
- 2013-12-05 CR CR20200273A patent/CR20200273A/es unknown
- 2013-12-05 HU HUE13817739A patent/HUE038238T2/hu unknown
- 2013-12-05 GE GEAP201313863A patent/GEP201706718B/en unknown
- 2013-12-05 SI SI201330958T patent/SI2935238T1/en unknown
- 2013-12-05 LT LTEP13817739.9T patent/LT2935238T/lt unknown
- 2013-12-05 SI SI201331756T patent/SI3339303T1/sl unknown
- 2013-12-05 MY MYPI2020003405A patent/MY192259A/en unknown
- 2013-12-05 WO PCT/IB2013/060682 patent/WO2014097041A1/fr active Application Filing
- 2013-12-05 AP AP2015008574A patent/AP2015008574A0/xx unknown
- 2013-12-05 JP JP2015548808A patent/JP5909308B2/ja active Active
- 2013-12-05 MX MX2015008058A patent/MX2015008058A/es active IP Right Grant
- 2013-12-05 RS RS20180103A patent/RS56815B1/sr unknown
- 2013-12-05 KR KR1020157019806A patent/KR101712441B1/ko active IP Right Grant
- 2013-12-05 DK DK13817739.9T patent/DK2935238T3/en active
- 2013-12-05 ES ES13817739.9T patent/ES2658974T3/es active Active
- 2013-12-05 NZ NZ708801A patent/NZ708801A/en not_active IP Right Cessation
- 2013-12-05 CA CA2893339A patent/CA2893339C/fr active Active
- 2013-12-05 PL PL17206218T patent/PL3339303T3/pl unknown
- 2013-12-05 CU CU2015000062A patent/CU24414B1/es unknown
- 2013-12-05 BR BR112015014678-3A patent/BR112015014678B1/pt not_active IP Right Cessation
- 2013-12-05 AU AU2013365908A patent/AU2013365908C1/en not_active Ceased
- 2013-12-05 HU HUE17206218A patent/HUE050009T2/hu unknown
- 2013-12-05 CN CN201380066782.2A patent/CN104870435B/zh not_active Expired - Fee Related
- 2013-12-05 SG SG11201504076XA patent/SG11201504076XA/en unknown
- 2013-12-05 PT PT172062184T patent/PT3339303T/pt unknown
- 2013-12-05 DK DK17206218.4T patent/DK3339303T3/da active
- 2013-12-05 TR TR2018/02791T patent/TR201802791T4/tr unknown
- 2013-12-05 PT PT138177399T patent/PT2935238T/pt unknown
- 2013-12-05 MA MA38175A patent/MA38175B1/fr unknown
- 2013-12-18 US US14/132,567 patent/US9040515B2/en active Active
- 2013-12-18 TW TW102146910A patent/TWI546293B/zh not_active IP Right Cessation
- 2013-12-19 AR ARP130104902A patent/AR094174A1/es not_active Application Discontinuation
- 2013-12-20 UY UY0001038712A patent/UY38712A/es not_active Application Discontinuation
- 2013-12-20 UY UY0001035225A patent/UY35225A/es not_active Application Discontinuation
-
2014
- 2014-02-28 NO NO14709442A patent/NO2961649T3/no unknown
-
2015
- 2015-03-09 US US14/642,274 patent/US20150175572A1/en not_active Abandoned
- 2015-05-26 CR CR20150279A patent/CR20150279A/es unknown
- 2015-06-16 PH PH12015501367A patent/PH12015501367B1/en unknown
- 2015-06-18 IL IL239520A patent/IL239520B/en active IP Right Grant
- 2015-06-18 CL CL2015001733A patent/CL2015001733A1/es unknown
- 2015-06-18 TN TNP2015000281A patent/TN2015000281A1/fr unknown
- 2015-06-19 DO DO2015000157A patent/DOP2015000157A/es unknown
- 2015-06-19 ZA ZA2015/04437A patent/ZA201504437B/en unknown
- 2015-06-19 GT GT201500190A patent/GT201500190A/es unknown
- 2015-06-19 MX MX2020002924A patent/MX2020002924A/es unknown
- 2015-07-21 EC ECIEPI201531579A patent/ECSP15031579A/es unknown
- 2015-09-30 HK HK15109626.6A patent/HK1208866A1/xx not_active IP Right Cessation
-
2017
- 2017-05-03 US US15/585,880 patent/US10246433B2/en active Active
-
2018
- 2018-01-15 HR HRP20180060TT patent/HRP20180060T1/hr unknown
- 2018-02-05 CY CY20181100137T patent/CY1119883T1/el unknown
- 2018-09-05 ME MEP-2018-8A patent/ME02980B/fr unknown
-
2020
- 2020-07-30 HR HRP20201194TT patent/HRP20201194T2/hr unknown
- 2020-08-11 CY CY20201100746T patent/CY1123237T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA38175A1 (fr) | Lactames fusionnés à un aryle et hétéroaryle | |
MA40225A (fr) | Composés dihydroisoquinolinone substitués | |
MA45920A (fr) | Inhibiteurs de pyridopyrimidinone cdk2/4/6 | |
MA38138A1 (fr) | Dérivés inédits de quinolone | |
MA37142A3 (fr) | Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine | |
MX2016009403A (es) | Compuestos heterociclicos. | |
UA111770C2 (uk) | Інгібітори бромдомену | |
MX2014012695A (es) | Derivados de isoindolona. | |
MA39211A1 (fr) | Composés tricycliques comme agents anti-cancers | |
MA37400B1 (fr) | Composés hétérocyclyle en tant qu'inhibiteurs de mek | |
GEP20146146B (en) | Pyrrolopyrimidine compounds as inhibitors of cdk4/6 | |
TN2016000188A1 (fr) | Derives de purines 2,6-substitues et leur utilisation dans le traitement de troubles proliferatifs. | |
MX2013012776A (es) | Inhibidores de la tirosina cinasa de bazo que contienen aminopiridina. | |
MA38999A1 (fr) | Nouveaux composés hétérocycliques | |
MA37886A1 (fr) | Nouvelles pyridinones bicycliques | |
MA47301B1 (fr) | Inhibiteurs sélectifs de jak1 | |
MA38240A1 (fr) | Nouveaux composes dimeres substitues antagonistes de l'iap utiles pour le traitement du cancer, de preference des tumeurs solides | |
MA39152A1 (fr) | Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine | |
SA518390920B1 (ar) | مركبات فينوكسي أسيتاميد معالجة بإضافة حلقة | |
MA38679B1 (fr) | Modulateurs du récepteur de cxcr7 | |
MA40366A (fr) | Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines | |
TR201819805T4 (tr) | Flavaglin türevleri̇. | |
UA107455C2 (uk) | Похідні індолу як протиракові агенти | |
EA201650003A1 (ru) | Соединённые циклоалкилом дигетероциклические производные | |
MA38009B1 (fr) | Composes d'azaindoline substitues qui ont une activite inhibitrice de la proteine d'apoptose pour leurs utilisations dans le traitement et/ou la prophylaxie du cancer |